Drug Profile
Mirogabalin - Daiichi Sankyo Company
Alternative Names: DS 5565; Mirogabalin besilate; Mirogabalin besylate; TARLIGE; TarligeLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Acetic acids; Amines; Aminobutyric acids; Analgesics; Cyclohexanecarboxylic acids; Gabapentinoids; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuropathic pain; Postherpetic neuralgia
- Phase I Unspecified
- No development reported Pain
Most Recent Events
- 31 Jan 2023 Preregistration for Neuropathic pain in China (PO) prior to January 2023
- 31 Jan 2023 National Medical Products Administration accepts marketing application for mirogabalin for Neuropathic pain for review
- 24 Jan 2022 Daiichi Sankyo completes a phase-III clinical trial in Neuropathic pain in China (PO) (NCT04094662)